ImmunoCellular soars on hope for ICT-107-Cedars-Sinai report
From the IV MB:
ImmunoCellular soars on hope for ICT-107
ImmunoCellular soars on hope for ICT-107 • 2:03 PM
ImmunoCellular Therapeutics (IMUC +22.9%) rallies hard after Cedars-Sinai provides an update on a study of ICT-107 in glioblastoma multiforme.
Eight of sixteen patients survived for longer than five years post-diagnosis.
Six patients were progression free at five years.
Four patients are still free of disease with "good quality of life at lengths from 65.1-82.7 months following diagnosis." (PR)
As for the Street's take: Roth adds IMUC to its Focus List. Price target is $9.
" Didn't Joe Springer on SA discuss these results weeks ago?"
yes he did, but Joe is a stock analyst/picker and a damn good one, but Cedar Sinai is synonymous with best in class and provides legitimacy to the prospects of IMUC!